ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Cardiovascular"

  • Abstract Number: 0141 • ACR Convergence 2024

    The Effect of Systemic Immunosuppressive Therapies on Cardiovascular Risk in Psoriatic Arthritis Patients

    Melody Esmaeili1, Linh Truong2, Nicole Ridolfi3, Eugenia Chen4 and Maida wong5, 1University of California, Irvine, Orange, CA, 2University of California, Los Angeles, Los Angeles, CA, 3University of California, Irvine, Newport Beach, CA, 4Long Beach VA Hospital, Irvine, CA, 5Long Beach VA Hospital, Los Angeles, CA

    Background/Purpose: Evidence demonstrates an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) among psoriatic arthritis (PsA) patients. However, the relationship between immunosuppressive therapies and the development of ASCVD remains unclear.…
  • Abstract Number: 0482 • ACR Convergence 2024

    Endothelial Dysfunction and QRISK3 in Rheumatoid Arthritis

    Vanshika Sabharwal1 and Ashit Syngle2, 1MMDU, Mullana, Ambala India and Healing Touch city clinic, Chandigarh, India, Chandigarh, Chandigarh, India, 2Healing Touch City Clinic, Chandigarh, Chandigarh, India

    Background/Purpose: CV disease is leading cause of morbidity and mortality in RA, largely due to endothelial dysfunction.1. Endothelial function is barometer of total cardiovascular risk while…
  • Abstract Number: 0807 • ACR Convergence 2024

    Evaluating Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus (SLE) and SLE Subgroups: Additional Risks Associated with Cardiovascular Events

    Rashmi Dhital1, Rebecca Baer2, Kenneth Kalunian3 and Christina Chambers4, 1UC San Diego, Brentwood, TN, 2UC San Diego, San Diego, 3University of California San Diego, La Jolla, CA, 4University of California, San Diego, La Jolla, CA

    Background/Purpose: Systemic Lupus Erythematosus (SLE) presents substantial risks for both maternal cardiovascular events (CVEs) and adverse pregnancy outcomes, yet, the influence of maternal CVEs on…
  • Abstract Number: 1119 • ACR Convergence 2024

    Treatment Outcomes of TNF-α Inhibitors in Cardiac Sarcoidosis

    Kailey Singh1, Harrison Zucker1, Alice Kwon2, Audrey Liu3, Josephine Rini1, Elena Katzap4, Sonali Narain5 and Galina Marder6, 1Northwell Health at Northshore/Long Island Jewish, Manhasset, 2Northwell Health at Northshore/Long Island Jewish, Bayside, NY, 3Loma Linda University, Loma Linda, CA, 4Northwell Health, Great NY, NY, 5Northwell Health, Great Neck, NY, 6Donald and Barbara Zucker School of Medicine at Hofstra/ Northwell, Great Neck, NY

    Background/Purpose: Management of cardiac sarcoidosis remains controversial. Our study aimed to describe our experience using tumor necrosis factor-α-inhibitors (aTNF) in cardiac sarcoidosis treatment.Methods: This is a…
  • Abstract Number: 1557 • ACR Convergence 2024

    Estimation of Cardiovascular Risk in Patients with Systemic Sclerosis – Accuracy of Tools Based on SCORE and Its Modifications Compared to Ultrasound Examination of Subclinical Atherosclerosis

    Sabína Oreská1, Aneta Prokopcová2, Hana Storkanova1, Jaroslav Kudlicka3, Vladimir Tuka4, Ondrej Mikes4, Zdislava Krupickova4, Martin Satny4, Eva Chytilova4, Jan Kvasnicka4, Maja Spiritovic5, Barbora Hermankova6, Petr Cesak7, Marian Rybar8, Karel Pavelka9, Ladislav Šenolt2, Radim Becvar1, Jiří Vencovský2, Michal Vrablik4 and Michal Tomcik1, 1Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 2Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 3Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 43rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, 5Institute of Rheumatology, Prague, Czech Republic, Prague, 6Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, 7Department of Human Movement Laboratory, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, 8Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, Kladno, Czech Republic, Kladno, 9Institute of Rheumatology and Charles University, Praha, Czech Republic

    Background/Purpose: Patients with systemic sclerosis (SSc) have increased cardiovascular (CV) risk due to accelerated atherosclerosis (ATS) caused by systemic inflammation, and vascular impairment. To date,…
  • Abstract Number: 2009 • ACR Convergence 2024

    Risk of Incident Gout and Cardiovascular Events Within 120 Days of Incident Gout with the Use of Insulin Glargine, Glucagon-like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Veterans with Type 2 Diabetes

    Amara Sarwal1, Augustine Takyi1, Guo Wei1, McKenna Nevers1, Ravinder Singh1, Sydney Hartsell1, Robert Boucher1, Niharika Katkam1, Akhil Chakravartula1, Jincheng Shen1, Srinivasan Beddhu1 and Naomi Schlesinger2, 1University of Utah, VA Salt Lake City Health Care System, Salt Lake City, UT, 2University of Utah, Salt Lake City, UT

    Background/Purpose: Previous studies compared the risk of gout with sodium-glucose cotransporter-2 inhibitors (SGLT2i) versus glucagon-like peptide-1 receptor agonists (GLP1-RA), including exendin-4 based GLP1-RA (exenatide and lixisenatide). Synthetic…
  • Abstract Number: 2499 • ACR Convergence 2024

    Description of Patients with Kawasaki Disease Shock Syndrome at a Large Tertiary Center

    Jessica Nguyen1, Danielle Guffey2, Andrea Ramirez1, Jamie Lai3, Tiphanie Vogel1, S. Kristen Sexson Tejtel1, Cagri Yildirim-Toruner4 and Marietta De Guzman1, 1Baylor College of Medicine, Houston, TX, 2Baylor College of Medicine, Houston, 3Baylor College of Medicine, The Woodlands, TX, 4Baylor College of Medicine/ Texas Children's Hospital, Houston, TX

    Background/Purpose: Kawasaki disease shock syndrome (KDSS) is a phenotype of Kawasaki disease (KD) associated with higher rates of refractory KD (RKD) and coronary artery aneurysms…
  • Abstract Number: 0143 • ACR Convergence 2024

    Behavioral Factors and Chronic Conditions Associated with Rheumatoid Arthritis, KNHANES 2010 to 2021

    GI HYUN MYUNG and Juwon Lim, Seoul National University Hospital, Seoul, Republic of Korea

    Background/Purpose: Rheumatoid arthritis (RA) is associated with multiple genetic and environmental factors. In terms of environmental, dietary and lifestyle factors, there have been discrepancies on…
  • Abstract Number: 0487 • ACR Convergence 2024

    The Triglyceride to HDL Ratio, a Surrogate Marker of Insulin Resistance, Predicts All Cause and Cardiovascular Mortality in Rheumatoid Arthritis

    Jose Felix Restrepo Suarez1, Carlos Lorenzo1, Inmaculada Del rincon2 and Agustin Escalante1, 1UT Health San Antonio, San Antonio, TX, 2UT Health San Antonio, San Antonio

    Background/Purpose: The triglyceride to HDL cholesterol (TG/HDL) ratio, a recognized surrogate marker of insulin resistance, has emerged as a predictor of cardiovascular (CV) risk. However,…
  • Abstract Number: 0841 • ACR Convergence 2024

    Clinical and Biologic Predictors of Thrombosis in Persistently Antiphospholipid Antibody Positive Patients: Prospective Analysis of the International APS ACTION Clinical Database and Repository (“Registry”)

    Jonathan Thaler1, Michael Parides1, Danieli Andrade2, Diana Paredes-Ruiz3, Maria Tektonidou4, Vittorio Pengo5, Savino Sciascia6, Cecilia Nalli7, Guilherme Ramires de Jesús8, Paul Fortin9, Maria Efthymiou10, H Michael Belmont11, Michelle Petri12, Ricard Cervera13, Leslie Skeith14, TATSUYA ATSUMI15, Chary Lopez-Pedrera16, Yu Zuo17, David Branch18, Rohan Willis19, Nina Kello20, Zhuoli Zhang21, Esther Rodriguez-Almaraz22, Bahar Artim Esen23, Jose Pardos-Gea24, Guillermo Pons-Estel25, Giulia Pazzola26, Hui Shi17, Ali Duarte-Garcia27, Medha Barbhaiya1, Cécile Yelnik28, Pierluigi Meroni29, Robert Roubey30, Maria Laura Bertolaccini31, Hannah Cohen32, Jacob Rand33 and Doruk Erkan1, and on behalf of APS ACTION, 1Hospital for Special Surgery, New York, NY, 2University of São Paulo, São Paulo, SP, Brazil, 3Autoimmune Diseases Research Unit. Biocruces Bizkaia Health Research Institute, Baracaldo, Spain, 4National and Kapodistrian University of Athens, Athens, Greece, 5Thrombosis Research Laboratory, Department of Cardio-Thoracic-Vascular Sciences and Public Health, University of Padova, Padova, Italy, 6University of Turin, Torino, Turin, Italy, 7ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, 8Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, 9Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, 10University College London, London, United Kingdom, 11NYU School of Medicine, New York, NY, 12Johns Hopkins University School of Medicine, Timonium, MD, 13Hospital Clinic de Barcelona, Barcelona, Spain, 14University of Calgary, Calgary, ON, Canada, 15Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, 16IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, 17University of Michigan, Ann Arbor, MI, 18University of Utah and Intermountain Healthcare, Salt Lake City, UT, 19University of Texas Medical Branch, Galveston, TX, 20Northwell Health, Brooklyn, NY, 21Peking University First Hospital, Beijing, China, 22Hospital Universitario 12 de Octubre, Madrid, Spain, 23Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, 24Vall d'Hebron University Hospital, Barcelona, Spain, 25CREAR, Rosario, Argentina, 26Rheumatology Unit, Azienda USL IRCCS di Reggio Emilia, Reggio Emilia, Italy, 27Mayo Clinic, Rochester, MN, 28lille university, Lille, France, 29IRCCS Istituto Auxologico Italiano 100%, Cusano Milanino, Milan, Milan, Italy, 30Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, 31King's College London, London, United Kingdom, 32University College London Hospitals NHS Foundation Trust, London, United Kingdom, 33Weill Cornell Medical Center, Bronx, NY

    Background/Purpose: There is a lack of high-quality data to inform risk-stratified long-term thrombosis prevention strategies in patients with persistently positive antiphospholipid antibodies (aPL). The APS…
  • Abstract Number: 1133 • ACR Convergence 2024

    Relationship Between Nail Psoriasis Severity Index (NAPSI) and Cardiovascular Risk Assessed by Eight Cardiovascular Risk Calculators

    Maria F. Elizondo-Benitez1, Iris Jazmín Colunga Pedraza2, jose Ramon Azpiri-Lopez3, Dionicio Galarza-Delgado4, Jesus Cardenas-de la Garza5, Rosa Icela Arvizu-Rivera2, Andrea Guajardo Aldaco2 and Valeria Gonzalez-Gonzalez6, 1Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 2Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 3Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 4UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, 5Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, 6Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic, inflammatory, and immune-mediated disease that affects up to 30% of psoriasis (PsO) patients. Nail psoriasis affects 80% of…
  • Abstract Number: 1567 • ACR Convergence 2024

    Systemic Sclerosis Is Associated with Sub-Clinical Abnormalities in Myocardial Energetics, Perfusion and Increased Fibrosis

    Chin Yit Soo1, Nicholas Jex2, Stefano Di Donato3, Lucy Elizabeth Thornton4, Vishal Kakkar5, Riccardo Bixio6, Raluca Tomoaia1, Thomas Anderton2, May Lwin2, Christel Kamani2, Amrit Chowdhary2, Henry Procter1, Sharmaine Thirunavukarasu1, Sindhoora Kotha2, Marilena Giannoudi2, Eylem Levelt2, Sven Plein1, Francesco Delgado6 and Lesley-Anne Bissell7, 1Multidisciplinary Cardiovascular Research Centre and Biomedical Imaging Science Department, University of Leeds, Leeds, United Kingdom., Leeds, England, United Kingdom, 2Multidisciplinary Cardiovascular Research Centre and Biomedical Imaging Science Department, University of Leeds, Leeds, United Kingdom., Leeds, United Kingdom, 31. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Leeds, United Kingdom, 41. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Leeds, 5University of Leeds, Leeds, United Kingdom, 6Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom., Leeds, United Kingdom, 7Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Background/Purpose: Primary cardiac involvement in systemic sclerosis (SSc) is heterogenous, poorly defined and associated with significant cardiac morbidity and mortality. The underlying mechanism is not…
  • Abstract Number: 2038 • ACR Convergence 2024

    Nationwide Analysis of Adult Hospitalizations with Rheumatologic Conditions and Spontaneous Coronary Artery Dissection

    Maria Romero Noboa1, Husam El Sharu2, Diego Cornejo3, Rafaella Litvin4 and Almurtada Razok4, 1University of Alabama at Birmingham, Chicago, IL, 2East Carolina University, Greenville, NC, 3John H Stroger Hospital of Cook County, Chicago, 4John H Stroger Jr Hospital of Cook County, Chicago, IL

    Background/Purpose: Rheumatic diseases have a higher risk of cardiovascular events, particularly those related to atherothrombosis which represents the leading cause of premature mortality in most of…
  • Abstract Number: 2500 • ACR Convergence 2024

    Description of Patients with Refractory Kawasaki Disease at a Large Tertiary Center

    Jessica Nguyen1, Danielle Guffey2, Andrea Ramirez1, Jamie Lai3, Tiphanie Vogel1, S. Kristen Sexson Tejtel1, Cagri Yildirim-Toruner4 and Marietta DeGuzman1, 1Baylor College of Medicine, Houston, TX, 2Baylor College of Medicine, Houston, 3Baylor College of Medicine, The Woodlands, TX, 4Baylor College of Medicine/ Texas Children's Hospital, Houston, TX

    Background/Purpose: Kawasaki disease (KD) is the leading cause of acquired heart disease in developed countries due to the development of coronary artery aneurysms (CAAs). Intravenous…
  • Abstract Number: 0147 • ACR Convergence 2024

    Clinical Characteristics and Biomarkers Associated with Detectable High-Sensitivity Cardiac Troponin in Patients with Rheumatoid Arthritis

    Ilana Usiskin1, Mary Jeffway1, Feng Liu1, Nancy Shadick1, Michael Weinblatt2, Brittany Weber3 and Katherine Liao1, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, 3Brigham and Women's Hospital, DEDHAM, MA

    Background/Purpose: General population-based cardiovascular (CV) risk estimators are known to underestimate CV risk in RA. High-sensitivity cardiac troponin T (hs-cTnT), typically measured during a work-up…
  • 1
  • 2
  • 3
  • …
  • 31
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology